{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:21:06Z","timestamp":1791418866038,"version":"4.3.3"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":549,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hum. Psychopharmacol Clin Exp"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1002\/hup.2388","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T02:43:04Z","timestamp":1393900984000},"page":"203-210","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects"],"prefix":"10.1002","volume":"29","author":[{"given":"Tianmei","family":"Si","sequence":"first","affiliation":[{"name":"Department of Clinical Psychopharmacology; Peking University Institute of Mental Health; Beijing China"},{"name":"Key Laboratory of Mental Health; Ministry of Health (Peking University); Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun'ai","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology; Peking University Institute of Mental Health; Beijing China"},{"name":"Key Laboratory of Mental Health; Ministry of Health (Peking University); Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology; Peking University Institute of Mental Health; Beijing China"},{"name":"Key Laboratory of Mental Health; Ministry of Health (Peking University); Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology; Peking University Institute of Mental Health; Beijing China"},{"name":"Key Laboratory of Mental Health; Ministry of Health (Peking University); Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Rui","sequence":"additional","affiliation":[{"name":"China R&D and Scientific Affairs; Xi'an Janssen Pharmaceutical Ltd; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology; Peking University Institute of Mental Health; Beijing China"},{"name":"Key Laboratory of Mental Health; Ministry of Health (Peking University); Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,3]]},"reference":[{"key":"10.1002\/hup.2388-BIB0001|hup2388-cit-0001","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1002\/hup.2388-BIB0003|hup2388-cit-0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1742-1241.2009.02240.x","article-title":"Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication","volume":"64","author":"Citrome","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"suppl1","key":"10.1002\/hup.2388-BIB0004|hup2388-cit-0004","article-title":"Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150\u2009mg eq., a new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles","volume":"83","author":"Cleton","year":"2008a","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl1","key":"10.1002\/hup.2388-BIB0005|hup2388-cit-0005","article-title":"Evaluation of the pharmacokinetic profile of gluteal versus deltoid intramuscular injections of paliperidone palmitate 100\u2009mg\u2009equivalent in patients with schizophrenia","volume":"83","author":"Cleton","year":"2008b","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/hup.2388-BIB0006|hup2388-cit-0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2388-BIB0007|hup2388-cit-0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchromb.2008.04.041","article-title":"Validated LC-MS\/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine","volume":"870","author":"De Meuldera","year":"2008","journal-title":"J Chromatogr B"},{"key":"10.1002\/hup.2388-BIB0008|hup2388-cit-0008","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1185\/03007990903482772","article-title":"Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia","volume":"26","author":"Gopal","year":"2010a","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/hup.2388-BIB0009|hup2388-cit-0009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010b","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/hup.2388-BIB0010|hup2388-cit-0010","volume-title":"NCDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976","edition":"3"},{"key":"10.1002\/hup.2388-BIB0011|hup2388-cit-0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hup.1085","article-title":"Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety","volume":"25","author":"Hawley","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/hup.2388-BIB0012|hup2388-cit-0012","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","article-title":"Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia","volume":"33","author":"Hough","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1002\/hup.2388-BIB0013|hup2388-cit-0013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2388-BIB0014|hup2388-cit-0014","volume-title":"(paliperidone palmitate) extended-release injectable suspension","author":"Invega\u00ae","year":"2010"},{"key":"10.1002\/hup.2388-BIB0016|hup2388-cit-0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2388-BIB0017|hup2388-cit-0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1002\/hup.2388-BIB0018|hup2388-cit-0018","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4088\/JCP.v64n1105","article-title":"Partial compliance and patient consequences in schizophrenia: our patients can do better","volume":"64","author":"Keith","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/hup.2388-BIB0019|hup2388-cit-0019","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1176\/appi.ps.55.9.997","article-title":"Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia","volume":"55","author":"Keith","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1002\/hup.2388-BIB0020|hup2388-cit-0020","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1461145709990988","article-title":"Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study","volume":"13","author":"Kramer","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1002\/hup.2388-BIB0021|hup2388-cit-0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2388-BIB0022|hup2388-cit-0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/hup.1108","article-title":"Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome","volume":"25","author":"Lloyd","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/hup.2388-BIB0023|hup2388-cit-0023","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1002\/hup.2388-BIB0024|hup2388-cit-0024","first-page":"1172","article-title":"How to examine patients using the Abnormal Involuntary Movement Scale","volume":"39","author":"Munetz","year":"1988","journal-title":"Hosp Community Psychiatry"},{"key":"10.1002\/hup.2388-BIB0025|hup2388-cit-0025","unstructured":"Nasrallah H Gopal S Kern-Sliwa J et al 2008 Efficacy and safety of three doses of paliperidone palmiate, an investigational long-acting injectable antipsychotic in schizophrenia 161st Annu Meet Am Psychiatr Assoc"},{"key":"10.1002\/hup.2388-BIB0026|hup2388-cit-0026","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1358\/dot.2007.43.4.1067342","article-title":"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic","volume":"43","author":"Owen","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1002\/hup.2388-BIB0027|hup2388-cit-0027","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/hup.2388-BIB0028|hup2388-cit-0028","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","article-title":"Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic","volume":"48","author":"Samtani","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/hup.2388-BIB0029|hup2388-cit-0029","first-page":"829","article-title":"Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data","volume":"25","author":"Samtani","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1002\/hup.2388-BIB0030|hup2388-cit-0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/hup.1132","article-title":"Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects","volume":"25","author":"Si","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/hup.2388-BIB0031|hup2388-cit-0031","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1002\/hup.2388-BIB0032|hup2388-cit-0032","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors","volume":"30","author":"Valenstein","year":"2004","journal-title":"Schizophr Bull"},{"key":"10.1002\/hup.2388-BIB0033|hup2388-cit-0033","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","article-title":"Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans","volume":"36","author":"Vermeir","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/hup.2388-BIB0034|hup2388-cit-0034","first-page":"106","article-title":"Medication noncompliance in schizophrenia, Pt 1: assessment","volume":"3","author":"Weiden","year":"1997","journal-title":"J Pract Psychiatry Behav Health"},{"key":"10.1002\/hup.2388-BIB0035|hup2388-cit-0035","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden","year":"2004","journal-title":"Psychiatr Serv"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2388","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/hup.2388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T18:39:59Z","timestamp":1625164799000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2388"}},"subtitle":["PALIPERIDONE PALMITATE PHARMACOKINETICS"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1002\/hup.2388","relation":{},"ISSN":["0885-6222"],"issn-type":[{"value":"0885-6222","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}